SpringWorks Therapeutics (SWTX) News Today → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free SWTX Stock Alerts $41.46 -1.15 (-2.70%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 4:35 AM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stake Lowered by Dimensional Fund Advisors LPDimensional Fund Advisors LP cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 4.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 968,405 shares of the company's stocMay 31 at 8:28 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)May 30 at 3:35 PM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by M28 Capital Management LPM28 Capital Management LP lowered its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 27.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 142,800 shares of the company's stock after selling 54,900 shares during the perMay 29, 2024 | marketbeat.com73,949 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Monashee Investment Management LLCMonashee Investment Management LLC bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 73,949 shares of the company's stock,May 27, 2024 | investing.comSpringWorks Therapeutics Inc (SWTX)May 27, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Increases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Charles Schwab Investment Management Inc. grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 18.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 501,067 shares of the company's stocMay 23, 2024 | globenewswire.comSpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Quotes and News SummaryMay 21, 2024 | marketbeat.comAssenagon Asset Management S.A. Takes Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Assenagon Asset Management S.A. purchased a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 50,978 shares of the cMay 20, 2024 | marketbeat.com101,126 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Bridger Management LLCBridger Management LLC purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 101,126 shares ofMay 20, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 3.5%SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 3.5%May 19, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Buys 60,652 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Massachusetts Financial Services Co. MA raised its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 14.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 468,078 shares of the company's stock after buying an additional 60,652May 15, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Rating of "Buy" from BrokeragesSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price amonMay 12, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Victory Capital Management Inc.Victory Capital Management Inc. grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 795.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 369,367 shares of the company's stock after acquiring an additional 328,127 shaMay 8, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceMay 6, 2024 | markets.businessinsider.comStrong Buy Rating for Springworks Therapeutics Amidst Ogsiveo’s Market Success and Robust PipelineMay 6, 2024 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday.May 5, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Announces Earnings ResultsSpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) posted its earnings results on Thursday. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The firm had revenue of $21.00 million for the quarter, compared to analyst estimates of $12.07 million. During the same quarter last year, the firm posted ($1.18) earnings per share. The business's revenue was up 2000.0% compared to the same quarter last year.May 3, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationMay 2, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)Wedbush restated an "outperform" rating and set a $75.00 price objective (up from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday.May 2, 2024 | markets.businessinsider.comBuy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising PipelineMay 2, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeSpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume IncreaseMay 2, 2024 | investorplace.comSWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024May 2, 2024 | washingtonpost.comSpringWorks Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesMay 1, 2024 | msn.comSpringWorks Therapeutics Q1 2024 Earnings PreviewApril 25, 2024 | seekingalpha.comSpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer ClearApril 24, 2024 | globenewswire.comSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 20, 2024 | marketbeat.comMutual of America Capital Management LLC Invests $2.34 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Mutual of America Capital Management LLC purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 64,214 shares of the companApril 19, 2024 | seekingalpha.comSpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire WinnersApril 19, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 3%SpringWorks Therapeutics (NASDAQ:SWTX) Trading 3% HigherApril 18, 2024 | globenewswire.comSpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024April 15, 2024 | nasdaq.comSWTX Quantitative Stock AnalysisApril 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Has $1.49 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)DekaBank Deutsche Girozentrale grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 131.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the company'sApril 11, 2024 | marketbeat.comPeregrine Capital Management LLC Has $4.96 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Peregrine Capital Management LLC cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 14.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 136,009 shares of the company's sMarch 26, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Recommendation of "Buy" from AnalystsShares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) have earned an average rating of "Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target aMarch 17, 2024 | finance.yahoo.comSWTX Apr 2024 70.000 callMarch 16, 2024 | marketbeat.comWalleye Capital LLC Increases Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Walleye Capital LLC grew its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 196.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 144,307 shares of the company's stock after buying an additional 95,694 shares during the quarter. WalleyeMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 11, 2024 | marketbeat.comEquities Analysts Issue Forecasts for SpringWorks Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2024 EPS estimates for shares of SpringWorks Therapeutics in a research note issued to investors on Wednesday, March 6th. HC Wainwright analyst R. Burns now forecasts that the compaMarch 8, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Reaches New 52-Week High at $53.92SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 52-Week High at $53.92March 6, 2024 | finance.yahoo.comSWTX Apr 2024 60.000 putMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 65.000 callMarch 6, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Price Target Raised to $74.00HC Wainwright lifted their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a "buy" rating in a research note on Wednesday.March 4, 2024 | globenewswire.comSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNMarch 4, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stake Lessened by Deutsche Bank AGDeutsche Bank AG reduced its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 59.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,671 shares of the company's stockFebruary 29, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) PT Raised to $63.00 at BarclaysBarclays upped their target price on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an "overweight" rating in a research note on Thursday. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. SWTX Media Mentions By Week SWTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SWTX News Sentiment▼0.950.76▲Average Medical News Sentiment SWTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SWTX Articles This Week▼83▲SWTX Articles Average Week Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Allogene Therapeutics News Today Replimune Group News Today bluebird bio News Today AlloVir News Today Bio-Techne News Today Qiagen News Today Repligen News Today Vaxcyte News Today Revolution Medicines News Today Exelixis News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SWTX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.